Experienced in Diffuse Large B-Cell Lymphoma (DLBCL)

Mojca Lavrencic-Jongen

Rotterdam, ZH, NL 
Experienced in Diffuse Large B-Cell Lymphoma (DLBCL)
Rotterdam, ZH, NL 
OverviewLocationsClinical Research

Overview

Mojca Lavrencic-Jongen practices in Rotterdam, Netherlands. Lavrencic-Jongen is rated as an Experienced expert by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Their top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Adult T-Cell Leukemia, and Bone Marrow Transplant.

Their clinical research consists of co-authoring 55 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Rotterdam, ZH, Netherlands
Other Locations
Zwolle, OV, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 1, Multinational Study of MCLA-117 in Acute Myelogenous Leukemia
A Phase 1, Multinational Study of MCLA-117 in Acute Myelogenous Leukemia
Enrollment Status: Terminated
Publish Date: April 06, 2025
Intervention Type: Drug
Study Drug: MCLA-117
Study Phase: Phase 1
A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed or Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed or Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

55 Total Publications

Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study.
Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study.
Journal: Leukemia & lymphoma
Published: May 07, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Lavrencic-Jongen's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile